Portage Biotech (US:PRTG) Newsfilter·2025-01-06 10:00Company Overview - Portage Biotech is a clinical-stage immuno-oncology company advancing a pipeline of novel biologics to enhance the immune system's ability to fight cancer [4] - Cyncado Therapeutics is a wholly-owned subsidiary of Portage Biotech, focused on developing best-in-class small molecule adenosine receptor antagonists targeting A2a and A2b receptors for oncology indications [5] Strategic Development - Portage Biotech re-launched its wholly-owned subsidiary as an independently managed company named Cyncado Therapeutics, with Peter Molloy appointed as CEO [1] - The re-launch aims to unlock the full potential of Portage's adenosine program and maximize value for shareholders [3] Therapeutic Focus - Cyncado Therapeutics is advancing A2a and A2b receptor antagonists, which are designed for dual administration to maximize synergy and achieve a comprehensive blockade of immune evasion pathways [2][5] - These therapeutics aim to enhance the immune system's ability to mount a robust anti-tumor response, potentially transforming immuno-oncology [2] Leadership and Vision - Peter Molloy, CEO of Cyncado Therapeutics, expressed confidence in the potential of adenosine pathway therapeutics and committed to advancing clinical programs toward proof of concept [3] - Alex Pickett, CEO of Portage Biotech, emphasized the strategic importance of the re-launch and Peter Molloy's expertise in accelerating clinical progress [3] Clinical and Financial Goals - Cyncado Therapeutics is focused on securing external financing and advancing clinical development to achieve proof-of-concept data for its therapeutics [2][3] - The company aims to establish its therapeutics as transformative treatments in oncology [3]